Characteristics of patients with resectable early-stage non–small cell lung cancer treated with neoadjuvant chemoimmunotherapy or surgery ± adjuvant therapy.
Randomized trial analyzes patient differences receiving neoadjuvant therapy versus surgery in early-stage NSCLC, suggesting ways to improve treatment use.
Key Points
This study aims to characterize differences in patient characteristics between those receiving neoadjuvant chemoimmunotherapy and those receiving surgery ± adjuvant therapy.
Adult patients with stage II-IIIB NSCLC identified from Flatiron Health database
Comparison of baseline characteristics using Pearson chi-square or Fisher exact tests
Statistical analyses were two-sided for significance testing.
1,807 patients identified; 204 (11%) received neoadjuvant ICI+CTx, 1,603 (89%) underwent surgery ± adjuvant therapy.
Neoadjuvant ICI+CTx group had higher stage III disease and PD-L1 positive expression levels.
Surgery ± adjuvant therapy group showed higher stage II disease and higher EGFR mutations (all p < 0.001).